No description available.

In the AcMNPV genome, ~28% of the genes are arranged divergently on opposite strands with an intergenic region of <1 kbp. In this configuration, a bidirectional promoter generally drives expression of both genes. However, no baculovirus bidirectional promoters have been characterized in any detail. We chose the AcMNPV chiA/v-cath intergenic region to serve as a model to characterize transcriptional regulation of bidirectional gene pairs during AcMNPV infection. We sequentially truncated putative upstream regulatory regions of chiA and v-cath to identify sequences essential for transcriptional initiation. Forty bp of the chiA gene 5’-flanking region was sufficient to support chiA transcription at half the level of the AcΔCC+CC repair virus. Interestingly, v-cath transcription from viruses containing only 40 bp of their upstream 5’-flanking region was found to be higher by 4-fold relative to the level of native expression. Linker-scanning mutagenesis that inserted 5 bp linkers spanning the chiA/v-cath intergenic region identified nucleotides critical for the transcriptional activation of both genes. From this, nucleotides -36 to -45, of the v-cath gene were found to negatively regulate v-cath mRNA expression. Quantitative RT-PCR studies revealed a 2-4 fold higher chiA mRNA expression relative to v-cath possibly explaining why translation of CHIA can be detected 6 hours earlier than V-CATH. This study identifies upstream regions of viral chiA and v-cath required for initiation of transcription and provides the first insight into baculovirus mechanisms for transcriptional regulation of interdependent gene pairs.

The proteinase, cathepsin L, has been strongly implicated in the processes of tumour invasion and metastasis. A new purification method, three-phase partitioning, characterised in terms of the parameters which affected its fractionation of proteins, was found to simplify the purification of cathepsin L from sheep liver. This method, together with a novel cation-exchange step on S-Sepharose and molecular exclusion chromatography, enabled the enzyme to be purified to homogeneity, in a single-chain form. A further enzyme fraction was isolated as a proteolytically active complex with the endogenous inhibitor of cysteine proteinases, cystatin. Studies on the proteolytically active complex revealed that approximately 60% of it was covalently bound and proteolytically active, while the other 40% was non-covalently bound and proteolytically inactive, in the manner normally found for the binding of cystatin to cysteine proteinases. A cystatin fraction from sheep liver containing variants of cystatin B, was shown to be able to form complexes with free cathepsin L in vitro in a pH-dependent, rapid process, which was mildly stimulated by a reducing agent. Cathepsin L was also isolated from human spleen, but only as a protcolytically inactive complex, presumably also with cystatin(s). The complexed and free cathepsin L from sheep liver were analysed for their pH-dependent characteristics, and it was found that both forms of the enzyme were more active and stable at, or near, neutral pH, than would have been expected from published values. Specific polyclonal antibodies to pure sheep cathepsin L were raised in rabbits and chickens. The chicken egg yolk antibodies were of a much higher titre and were immunoinhibitory towards the enzyme, which the rabbit antibodies were not. Anti-peptide antibodies, raised in rabbits against a peptide sequence selected from the active site of human cathepsin L, were highly specific for cathepsin L and immunoinhibitory towards the enzyme. Together with the polyclonal anti-cathepsin L antibodies, they show promise for immunoinhibitory and immunocytochemical studies on the enzyme, and as potential anti-tumour drugs. / Thesis (Ph.D.)-University of Natal, Pietermaritzburg, 1990.

Cathepsin L, which has been implicated in many tissue degradative pathologies by virtue of its ability to degrade extracellular matrix components, was isolated by a novel, scaled-up protein purification method and purified to homogeneity in the single-chain form. In addition, the high molecular weight variant of cathepsin L covalently complexed with stefin B was isolated. Both cathepsin L and the complex were stable, in respect of their proteolytic activity, to the chaotropic agent urea, both showing enhanced activity in the presence of urea. Urea did not dissociate the complex. The suitability of cathepsin L for a purported extracellular role was addressed by investigating its pH optimum and pH stability. Cathepsins L and B are affected by ionic strength and so buffers of constant ionic strength (rather than constant molarity, and therefore varying ionic strength) were used in determining their pH optima and stability. Cathepsins L and B had apparent pH optima of pH 6.5 and 7.5, respectively, (measured with synthetic substrates) and, contrary to the previous belief, were substantially stable at physiological pH. In Hanks' balanced salt solution, a model of the extracellular fluid, they were shown to be active and stable, cathepsin L having a half-life of 179 s at pH 7.2 and 657 s at pH 6.8 (the peritumour pH). It was also shown that prior reductive activation of these enzymes increased their stability to extracellular conditions, supporting the hypothesis that the active site thiolate-imidazolium ion pair contributes to their stability. The nature of the bond between cathepsin L and stefin B in the covalent complex was examined, using CNBr cleavage, HPLC and amino acid sequencing. Stefin B was shown to be associated with residues 1-137 of cathepsin L via a reduction sensitive linkage which was deduced to be a thioester bond betwen Asp-71 of cathepsin L and Cys-3 of stefin B. Polyclonal antibodies to cathepsin L and stefin B-complexed cathepsin L were raised in rabbits and chickens, and characterised with respect to their suitability for immunocytochemical localisation of these forms of cathepsin L. / Thesis (Ph.D.)-University of Natal, Pietermaritzburg, 1998.

Cathepsin, matrix metalloproteinase (MMP) enzyme and tissue inhibitor of MMP (TIMP) distribution in J774 mouse macrophages has not been comprehensively studied. The distribution and vesicle regulation, trafficking and release of these is important, possibly suggesting drug targets for the therapeutic regulation of inflammatory disease and phagosomal killing of pathogenic organisms in J774 and other macrophages. Percentage immunofluorescence and ultrastructural enzyme and inhibitor distribution, together with LysoTracker (acidity) and lysosome-associated membrane proteins (LAMPs) colocalisation (both indicating late endosome or “lysosomal” association), western blot estimates of percentage processed- and unprocessed intracellular and secreted enzyme and inhibitor, and vesicle size was used to assign enzyme and inhibitor to “classical” vesicle types. Antibodies against TIMP-1 and TIMP-2 were raised and all antibodies characterised for this purpose. Together these were used to assign cathepsins H, S, D, B and L to possible secretory vesicles (±20 nm, non-acidic, LAMPs-negative, containing precursor enzymes) and identify at least 6 other endosome-“lysosome-like” vesicles. Cathepsin H appears to be present in classical early endosomes (±100 nm, non-acidic, LAMPs-negative) and cathepsin S in late endosomes(±50 nm, acidic, LAMPs-positive) and possibly “lysosomal” (“hybrid” or digestive organelles) (±150-200 nm, acidic, LAMPs-positive). Both cathepsins H and S, however, seem only reliable markers if used together with additional markers. Cathepsin D appearsmainly associated with “lysosomal” (“hybrid” or digestive organelles) (±150-200 nm, acidic, LAMPs-positive), possibly consisting of further subpopulations which requires furtherinvestigation e.g. labelling for LAMP-1 and LAMP-2 and cathepsin D. Cathepsins B and Lmay occur in late endosomes and/or hybrid organelles and “secretory lysosomes” containing cathepsins B, D and L may also exist (±30-50 nm, acidic, LAMPs-positive). The distribution of MMP-9, TIMP-1 and -2 in vesicles (non-acidic, LAMP-2-negative) thatappear novel and distinct from late endosome-“lysosome” vesicles were also demonstrated. In LPS-stimulated cells, the identity of the large (±450 nm), possible recycling endosomes (Rab11-positive, LAMPs-negative), containing colocalised MMP-9 and TIMP-1, needs investigation i.e., requires further verification with triple labelling and EM. Possible cell membrane and recycling endosome localisation of TIMP-2 needs confirmation with labelling of non-permeabilised cells and labelling for MT1-MMP and proMMP-2, respectively. / Thesis (M.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2007.

Cancer is a disease that is caused by mutations in somatic cells. Metastasis is the major cause of death from cancer and often complicates treatment. Malignant tumours secrete degradative enzymes such as cathepsin L which degrade the extracellular matrix to facilitate tumour invasion and metastasis. The immune system does not normally recognize and eradicate tumours because they arise from self tissues to which the immune system is tolerant. Self antigens are poorly immunogenic because they lack T cell help. In this study, a foreign glucosidase was conjugated to self rabbit cathepsin L using glutaraldehyde to specifically provide T helper cell epitopes. The conjugate was used to immunise two male rabbits. A second pair of rabbits (male and female), was primed with sheep cathepsin L (to induce T helper cell activation) and received rabbit cathepsin L boosters. A third pair of rabbits which served as a control was immunised with sheep cathepsin L. The two pairs of test rabbits made high avidity antibodies against rabbit cathepsin L, showing a similar response to control rabbits when antibodies were tested in an ELISA. Western blot analysis showed that these anti-cathepsin L autoantibodies were specific for rabbit cathepsin L. Rabbits which were immunised with the conjugate were · inoculated with sheep cathepsin L nine weeks after the final inoculation with the conjugate. Analysis of antibodies in an ELISA showed that antibody responses against rabbit cathepsin L were augmented in a manner that is characteristic of memory responses. Low titre antibodies against sheep cathepsin L were also produced. / Thesis (M.Sc.)-University of KwaZulu-Natal, Pietermaritzburg, 2005.

Angiotensin II (Ang II) is an important modulator for development of atherosclerosis from early stage foam cell formation to advanced stage plaque rupture. Recently, the importance of locally generated Ang II, especially in macrophages, has become more evident. Generation of Ang II by several enzymes other than ACE and renin has been shown mainly in vitro. Cathepsin G is one these enzymes which is expressed in neutrophils and macrophages. Macrophages are one of the primary and crucial cells in atherosclerotic lesions which become lipid-laden foam cells through lipoprotein uptake. We hypothesized that activation of nuclear factors in foam cells increases Ang II by modulation of the renin angiotensin system (RAS) genes and cathepsin G. We also hypothesized that cathepsin G, through its Ang II generating activity and its other catalytic functions, promotes atherosclerosis. The present study assessed the Ang I and II levels and expression of the RAS genes in THP-1 cells, a human acute monocytic leukemia cell line, and in peritoneal and bone marrow-derived macrophages after exposure to acetylated LDL (ac-LDL). I also evaluated how RAS blockade would affect foam cell formation in THP-1 cells. In parallel, I assessed the role of cathepsin G in Ang II generation and in the progression of atherosclerosis in cathepsin G heterozygous knockout mice on an Apoe-/- background (Ctsg+/-Apoe-/- mice). Ac-LDL treatment increased Ang I and Ang II levels in cell lysates and media from THP-1 cells but not in peritoneal or bone marrow-derived macrophages from wild type C57BL/6 mice. In ac-LDL-treated THP-1 cells, ACE and cathepsin G mRNA levels and activities were elevated. Angiotensinogen mRNA is increased but not the angiotensinogen protein concentration. Renin mRNA level and activity were not altered by ac-LDL treatment. Blocking RAS by an AT1 receptor blocker, ACE inhibitors or a renin inhibitor decreased cholesteryl ester content of THP-1 cells after exposure to ac-LDL. To confirm that the Ang II effect on foam cell formation was not unique to ac-LDL, we treated the THP-1 macrophages with a renin inhibitor or an AT1 receptor inhibitor after exposure to oxidized LDL (ox-LDL). RAS blockade in ox-LDL-treated cells also abolished cholesteryl ester formation. To see how Ang II plays a role in foam cell formation we assessed the effect of RAS inhibitors on SR-A, the principal receptor for mediating ac-LDL entry into the cells and on acyl-CoA:cholesterol acyl transferase (ACAT-1), the enzyme responsible for intracellular cholesterol esterification. RAS blockade in both ac-LDL- and ox-LDL-treated cells decreased SR-A and ACAT-1 protein levels. Cathepsin G partial deficiency on an Apoe-/- background did not change Ang II levels in peritoneal or bone marrow-derived macrophage cell lysates or media. This deficiency also did not affect immunoreactive angiotensin peptide levels in atherosclerotic lesions. After 8 weeks on a high fat diet Ctsg+/-Apoe-/- mice were similar to Ctsg+/+Apoe-/- mice in terms of lesion size and serum cholesterol levels but the Ctsg+/+Apoe-/- mice had more advanced lesions with more collagen and smooth muscle cells and fewer macrophages. Moreover, Ctsg+/+Apoe-/- mice had more apoptotic cells than their Ctsg+/-Apoe-/- littermates. Overall, our findings indicate that Ang II is increased in foam cells and this endogenous Ang II is involved in cholesteryl ester formation, possibly by regulating the levels of ACAT-1 and SR-A. We did not find any role for cathepsin G in generation of Ang II in mice but cathepsin G does, nevertheless, promote the progression of atherosclerotic lesions to a more advanced stage.

Abstract In mammalian cells the pH gradient between the organelles, cytoplasm and extracellular space is strictly regulated. Maintenance of pH homeostasis is crucial for the normal function of the cell and its organelles. In solid tumours, cells often suffer from hypoxia, deprivation of nutrients and acidic extracellular milieu as a result of inadequate vascularisation. Cancer cells are also known to suffer from other pH abnormalities. Defective acidification of intracellular organelles as well as a reversed pH gradient across the plasma membrane have been detected in numerous tumour tissues and cells. Aberrant secretion of lysosomal hydrolases, loss of cell polarity and increased expression of tumour-specific proteins are common phenotypic changes of cancer cells. In this study, secretion of cathepsin D, a lysosomal aspartic hydrolase, was shown to result from the acidification defect of cancer cells. In normal cells cathepsin D is sorted in the Golgi complex by mannose-6-phosphate receptors and transported via endosomes to lysosomes. In breast and colorectal cancer cells having abnormally neutral endosomes receptors were shown to accumulate in endosomes resulting in the aberrant secretion of newly synthesised cathepsin D from the cells. Carcinoembryonic antigen (CEA) is an oncofetal protein widely used as a tumour follow-up marker. It is normally expressed at low levels and is localised at the apical surface of epithelial cells via a glycosyl phosphatidyl inositol (GPI) anchor. In cancer cells the expression of CEA is increased and the protein is found over the entire surface of cells. In this study, the tumour microenvironmental factors, hypoxia and abnormal pH homeostasis, were shown to increase the expression of carcinoembryonic antigen in cancer cells. In addition, the absence of acidic organelles was shown to induce mistargeting of CEA to the basolateral membrane in polarised cells. The abnormally neutral Golgi was found to interfere with the complex formation of carcinoembryonic antigen, a phenomenon recently associated with the apical sorting of other GPI-anchored proteins. Altogether these results emphasise the role of tumour-related factors – altered pH homeostasis and hypoxia – in the phenotypic changes of cancer cells.

La Cathepsine D (CathD) est une protéase lysosomale surexprimée et sécrétée par de nombreuses tumeurs solides. Cette enzyme favorise la prolifération tumorale et le processus métastatique, faisant d’elle une cible intéressante pour la thérapie anticancéreuse. Il existe un très bon inhibiteur de la CathD, la pepstatine, mais celui-ci traverse trop difficilement la membrane cellulaire pour être actif. C’est pourquoi des vecteurs de pénétration cellulaire, basés sur l’oligomérisation de mimes contraints de dipeptide, ont été développés au laboratoire. De ce travail, un bioconjugué, le JMV4463, a été développé. Composé d’un vecteur AMPA4 (tétramère de l’acide 2-(aminométhyl)phénylacétique), de la pepstatine, et d’une partie hydrophile aidant à la solubilisation du conjugué, ce bioconjugué est capable d’entrer dans les cellules et possède une activité antiproliférative sur différentes lignées de cellules cancéreuses. Partant de ce travail, la synthèse de nouveaux vecteurs potentiels de pénétration cellulaire, oligomères de mimes contraints de dipeptide, a été réalisée. Leur capacité d’internalisation a été établie sous la forme de conjugués avec la pepstatine. Les monomères envisagés étaient des analogues des motifs AMPA et acide (S)-2-(3-amino-4-oxo-3,4-dihydrobenzo[b][1,4]thiazépin-5(2H)-yl)acétique (DBT), motif ayant également montré une importante capacité d’internalisation. Ainsi, des analogues de l’AMPA en série indole, pyrrole et cyclohexane ont été préparés. De plus, la synthèse d’analogues de l’AMPA possédant différentes substitutions a été réalisée, tels que les méta- et para-AMPA, un homologue inférieur ou les 4,5-diméthoxy-, 4,5-dihydroxy- et 4-bromo-AMPA. Un analogue en série benzodiazépine du DBT a également été étudié. Tous les vecteurs correspondants sont capables d’internaliser la pepstatine dans les cellules mais, de façon surprenante, aucun des conjugués n’a montré d’activité anti-proliférative, indiquant un rôle essentiel du vecteur AMPA4. Une étude des relations structure / activité du JMV4463 a confirmé que le vecteur AMPA4 possédait un mode d’action unique mais celui-ci n’a pu être identifié à ce jour. Dans cette étude, il a également été montré qu’il était possible de simplifier la structure de la pepstatine, en remplaçant un de ses motifs statine par un motif gamma-alanine, permettant un coût de production réduit. Enfin, une étude in vivo sur un modèle xénogreffé de souris a montré un fort potentiel anti-tumoral du conjugué JMV4463. / Cathepsin D (CathD) is an overexpressed lysosomal protease secreted by several solid tumors. This enzyme is involved in tumor proliferation and metastasis, which makes it a promising target for cancer therapy. There exists a potent CathD inhibitor called Pepstatin, but it presents a too poor ability to cross the plasmic membrane in order to be active. To overcome this drawback, the development of cell penetrating vectors based on the oligomerization of constrained dipeptide mimetics has been undertaken in our lab. From this work, the bioconjugate JMV4463 has been developed. This bioconjugate is made of an AMPA4 (2-(aminomethyl)phenylacetic acid) vector, the pepstatin and a hydrophilic part which increases its solubility. This bioconjugate is able to penetrate the cells and has an antiproliferative effect on different cancer cell lines. Based on this work, synthesis of new potential cell penetrating vectors, oligomers of constrained dipeptide mimetics, was performed. Their internalization ability was established as their conjugate with pepstatin. We developed analogues of AMPA scaffold and (S)-2-(3-amino-4-oxo-3,4-dihydrobenzo[b][1,4]thiazépin-5(2H)-yl)acetic acid (DBT), which showed an important internalization ability. Thus, AMPA derivatives in indole, pyrrole and cyclohexane series were prepared. Furthermore, the synthesis of AMPA analogues having different substitutions on its aromatic part was performed, such as meta- and para- AMPA, an inferior homologue or 4,5-dimethoxy-, 4,5-dihydroxy- and 4-bromo-AMPA. An analogue of DBT in the benzodiazepin series has also been studied. All the corresponding vectors were able to internalize the pepstatin into the cells. Surprisingly, none of the conjugates showed an anti-proliferative activity, indicating the essential role of the AMPA vector. A structure/activity relationships study was performed for JMV4463. The obtained results confirmed that the AMPA vector has a unique mode of action that has not been identified yet. Furthermore, it has been demonstrated that it was possible to simplify the pepstatin structure by replacing one of its statin residues by a gamma alanine, which allows decreasing the production cost. Finally, an in vivo study on a xenografted mouse model showed a high anti-tumour potential for the JMV4463 conjugate.

Le cancer du sein triple-négatif est un sous-type représentant environ 15 % des cancers du sein, qui est caractérisé par l'absence de récepteurs hormonaux aux œstrogènes et à la progestérone et l'absence d'expression du facteur de croissance HER-2. Le cancer du sein triple-négatif est également associé à un profil clinique défavorable avec un haut risque de rechute métastatique précoce. Actuellement, de nombreuses molécules sont testées comme cible thérapeutique dans ce type de cancer. La cathepsine D, une aspartyl protéase lysosome, est un marqueur de mauvais pronostic du cancer du sein associé au risque métastatique. Cette protéase est surexprimée par les cellules cancéreuses mammaires et hypersécrétée dans le microenvironnement tumoral. Notre équipe a apporté des contributions importantes pour élucider le rôle de la cath-D dans le cancer du sein. La cath-D stimule la prolifération des cellules cancéreuses, la croissance et l'angiogenèse tumorales ainsi que la formation des métastases. Au niveau moléculaire, le proenzyme sécrété par la cellule tumorale stimule la croissance invasive du fibroblaste mammaire via le récepteur LRP1 (low-density lipoprotein receptor-related protein-1). De plus, au pH extracellulaire acide des tumeurs, la pro-cathepsine D secrétée dégrade un des plus puissants inhibiteurs des cystéines cathepsines, la cystatine C, stimulant ainsi leurs activités protéolytiques.Mon travail a consisté à développer des anticorps anti-cath-D, présentant un effet thérapeutique dans le cancer du sein triple-négatif. Nous avons utilisé deux approches l'une par la technologie des hybridomes qui a permis d'isoler 50 anticorps, qui se sont avérés être des IgM. L'autre, par phage display, où 8 anticorps fragments scFv anti-cath-D ont été sélectionnés par ELISA. Ces 8 scFv ont été criblés pour leur capacité à bloquer l'activité biologique de la cathepsine D : inhibition de l'interaction avec LRP1 et inhibition du clivage d'un substrat fluorescent. Les anticorps E2 et F1 reformatés en IgG1 inhibent in vitro le phénomène de cicatrisation, la clonogénéicité, la croissance tridimensionnelle dans le matrigel et in vivo la croissance tumorale des cellules de cancer du sein triple-négatif MDA-MB-231. Cette étude est une première étape vers le développement de thérapie anti-cath-D dans le cancer du sein. / Cancer is the leading cause of death in the developed world. This project focuses t on the high incidence triple-negative breast cancers (ER- and PR-negative, HER2-non amplified) who present unsatisfactory treatments. Tumor progression is known to be due to cross-talk between cancer cells and their surrounding supporting tissue, the tumor stroma. The lysosomal aspartic protease cathepsin D is over-produced and abnormally hypersecreted by epithelial breast cancer cells. This protease is an independent marker of poor prognosis in breast cancer correlated with the incidence of clinical metastasis. Cathepsin D stimulates tumor progression by both proteolytic and non-proteolytic molecular mechanisms. Our team has shown that secreted pro-cathepsin D can alter the tumor microenvironment by interacting with partners such as the LRP1 (low-density lipoprotein receptor-related protein-1) receptor, and/or by cleaving endogenous substrates like cystatin C. My pHD project aimed to target extracellular procathepsin D released in breast cancer by developing specific therapeutic antibodies to block its catalytic and binding capacities. We have isolated 50 hybridomas, that secreted IgM, a pentameric antibody format with high avidity but low affinity, and 8 anti-cath-D scFv by phage display. The anti-human cath-D scFv were selected by functional screenings for their ability to inhibit both the proteolytic activity of Cath-D and its binding to the fibroblastic LRP1 receptor. Two scFv cloned under IgG1 format (F1 and E2) inhibited wound healing, colony formation and three-dimensional outgrowth in Matrigel of MDA-MB-231 triple-negative breast cancer cells, and their tumor growth in athymic nude mice. Our findings strongly suggest that antibody-based targeting of Cath-D within the breast tumor microenvironment may have therapeutic efficacy for breast cancer treatment.